CORDIS
EU research results

CORDIS

English EN
Development of Robust and Innovative Vaccine Effectiveness

Development of Robust and Innovative Vaccine Effectiveness

Objective

Influenza is a major public health problem. In a conservative estimate, influenza infects annually 60 of the 500 million inhabitants of the EU. Vaccines are the cornerstone for preventing influenza and its consequences. Current influenza vaccines have a moderate variable effect, given the mismatch between vaccine and circulating strains, waning immunity and interference from previous vaccination, among others.

The single most important challenge in achieving VE studies for the various influenza vaccines put every year on the European market is the ability of the different stakeholders to work in collaboration.

To enable a sustainable network of influenza vaccine VE studies, the Development of Robust and Innovative Vaccines Effectiveness (DRIVE) main goal will be the development of a governance model between public and private entities. This model will ensure scientific independence in the studies and full transparency, allowing different stakeholders to fulfill their needs taking into account their respective obligations and statutes.

A second challenge will be to reach the capacity to perform vaccine brand- specific effectiveness studies, which is agile enough to deliver the needed outputs in timely manner, and robust enough to provide results by different age and risk groups and flexible enough to utilize novel tools while at the same time aims to be sustainable.

Combining these outputs, DRIVE will establish a sustainable platform for joint influenza vaccine effectiveness evaluation which will have a positive impact on European citizens public health.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

FUNDACION PARA EL FOMENTO DE LA INVESTIGACION SANITARIA Y BIOMEDICA DE LA COMUNITAT VALENCIANA

Address

Calle Micer Masco 31
46010 Valencia

Spain

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 5 684 187,50

Participants (14)

Sort alphabetically

Sort by EU Contribution

Expand all

INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT

France

EU Contribution

€ 303 687,50

P95 CVBA

Belgium

EU Contribution

€ 478 062,50

UNIVERSITA DEGLI STUDI DI FIRENZE

Italy

EU Contribution

€ 350 812,50

SYNAPSE RESEARCH MANAGEMENT PARTNERS SL

Spain

EU Contribution

€ 393 750

TERVEYDEN JA HYVINVOINNIN LAITOS

Finland

EU Contribution

€ 349 250

ISTITUTO SUPERIORE DI SANITA

Italy

EU Contribution

€ 382 500

UNIVERSITY OF SURREY

United Kingdom

EU Contribution

€ 257 375

CONFEDERATION OF MENINGITIS ORGANISATIONS LTD

United Kingdom

EU Contribution

€ 161 500

UNIVERSITE LYON 1 CLAUDE BERNARD

France

EU Contribution

€ 315 250

ASSOCIATION INTERNATIONALE DE STANDARDISATION BIOLOGIQUE POUR L'EUROPE (IABS-EU)

France

EU Contribution

€ 323 437,50

SANOFI PASTEUR SA

France

ABBOTT BIOLOGICALS BV

Netherlands

SEQIRUS UK LIMITED

United Kingdom

GLAXOSMITHKLINE BIOLOGICALS SA

Belgium

Project information

Grant agreement ID: 777363

Status

Ongoing project

  • Start date

    1 July 2017

  • End date

    30 June 2022

Funded under:

H2020-EU.3.1.7.12.

  • Overall budget:

    € 9 999 937,50

  • EU contribution

    € 8 999 812,50

Coordinated by:

FUNDACION PARA EL FOMENTO DE LA INVESTIGACION SANITARIA Y BIOMEDICA DE LA COMUNITAT VALENCIANA

Spain